Quarterly report pursuant to Section 13 or 15(d)

Fair Value (Narrative) (Details)

v3.2.0.727
Fair Value (Narrative) (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Mar. 11, 2015
Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]            
Derivative liabilities $ 63,000   $ 63,000     $ 0
Recurring            
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]            
Platinum notes payable 10,414,909   10,414,909     5,615,764
Derivative liabilities 63,000   63,000      
Transfers into Level 2 0 $ 0 0 $ 0    
Transfers out of Level 2 0 0 0 0    
Recurring | Significant Unobservable Inputs (Level 3)            
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]            
Platinum notes payable 10,414,909   10,414,909     5,615,764
Derivative liabilities 63,000   63,000      
Decrease (Increase) in fair value of Level 3 liabilities (1,900,000) (92,000) (126,000) 300,000    
Recurring | Quoted Prices in Active Markets for Identical Liabilities (Level 1)            
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]            
Platinum notes payable 0   0     $ 0
Derivative liabilities 0   0      
Liabilities at fair value $ 0 $ 0 $ 0 $ 0    
Macrophage Therapeutics | Common Stock            
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]            
Number of shares underlying warrant issued 300   300   300  
Macrophage Therapeutics | Convertible Preferred Stock            
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]            
Preferred stock issued         10